Sickle Cell Disease (Ongoing)

Posted On 2020-07-02 02:11:16



This Series on “Sickle Cell Disease” is edited by Dr. Carla Luana Dinardo from Fundação Pró-Sangue Hemocentro de São Paulo and Universidade de São Paulo, São Paulo, Brazil. The series will be dedicated to the presentation of different aspects of this complex disease, focusing on the physiopathology, target-organ complications and transfusion support, especially referring to RH variants.

Carla Luana Dinardo, MD, PhD
Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil; Instituto de Medicina Tropical, Universidade de São Paulo, São Paulo, Brazil

Dr. Carla Dinardo received her medical degree from the University of São Paulo School of Medicine in 2005. She then completed her residency training in internal medicine in 2008. She becomes a specialist in Hematology and Hemotherapy since 2010, and she initiated her career at Fundação Pró-Sangue São Paulo Hemocenter as head of the Immunohematology Division in 2012. She then received her PhD in Sciences from the University of São Paulo School of Medicine in 2015.

Dr. Dinardo currently serves as director of external relations of Fundação Pró-Sangue, coordinating the transfusion and the immunohematology reference laboratories. Dr. Dinardo is also head of the scientific department of the Hemotherapy Unit of Hospital Samaritano and head of the immunohematology reference laboratory of Hospital das Clínicas, University of São Paulo. She also joined the Young Professional Council of ISBT in 2020, representing Latin America.

Her main research focus is on studying the genetics of blood group systems and red blood cell alloimmunization. She is an active investigator of the Recipient Epidemiology and Donor Evaluation Study (REDS) IV-P and of the Trans-Omics for Precision Medicine (TOPMed) Consortium. She is currently Principal Investigator of seven studies and she has published about 50 articles in peer-review journals in the field of hematology, hemotherapy, cell physiology and genetics.

Series outline:

  1. Monocyte Monolayer Assay as a strategy to detect hyperhemolysis
  2. Pulmonary Hypertension in SCD
  3. Overview of the REDSIII SCD cohort
  4. RBC alloimmunization in SCD: from bench to bedside
  5. Clinical and laboratorial factors associated with SCD leg ulcers
  6. Hydroxyurea in SCD: new insights in the mechanisms of action
  7. Strategies to transfuse SCD patients presenting clinically relevant RH variants
  8. Hematopoietic Stem Cell Transplantation in SCD
  9. RBD deformability in vitro and survival in vivo
  10. Diversity of Beta-globin genes haplotypes in SCD